Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menu

Search BMS Clinical Trials
BMS Active Not Yet Recruiting Study icon

Active, Not Recruiting

Trial ID CA073-1022  |   NCT06425302

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

Celgene Corporation, a wholly owned subsidiary of Bristol-Myers Squibb Company

Warning icon
Sorry, this study is no longer accepting new participants, but is still ongoing.
You may click the “Check Your Eligibility” button and answer a few questions about your health to find out if you might be a match to another study.
Check Your Eligibility

Summary

  • Phase 2
  • Male and Female Gender icon
  • 18+
    Age Range
  • BMS Active Not Yet Recruiting Study icon
    Active, Not Recruiting

Overview

The purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL).

print Print
email Email

Key Eligibility Criteria

Inclusion Criteria

Inclusion Criteria Icon img
  • Participant has histologically confirmed Grade 1, 2 or 3a follicular lymphoma (FL) or classic FL. Formalin-fixed paraffin embedded (FFPE) archival tissue from 1 year prior to screening is allowed. If more than 1 year has passed, then a fresh biopsy must be obtained to confirm the diagnosis.
    1. Have no prior systemic treatment for follicular lymphoma. Prior radiation therapy or surgery for previously diagnosed stage I disease is acceptable.
      1. Stage II to IV disease.
        1. Deemed to need treatment by treating investigator. Reasons for treatment can include, but are not limited to, the following:.
          1. Bulky disease defined as:.
            1. A nodal or extra nodal (except spleen) mass > 7cm in its greater diameter or, involvement of at least 3 nodal or extra nodal sites (each with a diameter greater than >3 cm).
          2. Presence of at least one of the following B symptoms:.
            1. Fever (>38°C) of unclear etiology.
            2. Night sweats.
            3. Weight loss greater than 10% within the prior 6 months.
          3. Splenomegaly with inferior margin below the umbilical line.
            1. Any one of the following cytopenia due to lymphoma:.
              1. Platelets <100,000 cells/mm3 (100 x 109/L).
              2. Absolute neutrophil count (ANC) < 1,000 cells/mm3 (1.0 x 109/L).
              3. Hemoglobin < 10g/dL (6.25 mmol/L).
            2. Pleural or peritoneal serous effusion (irrespective of cell content).
              1. Any compressive syndrome (for example, but not restricted to ureteral, orbital, gastrointestinal).

              Exclusion Criteria

              Exclusion Criteria Icon
              • Clinical evidence of transformed lymphoma by investigator assessment.
                1. Follicular Large Cell as per WHO 5th classification or Grade 3b follicular lymphoma as per WHO 4th classification.
                  1. Participant has any significant medical condition, active infection, laboratory abnormality, or psychiatric illness that would prevent the participation in the study.
                    Additional Information *
                    • Other protocol-defined Inclusion/Exclusion criteria apply.

                      Treatment Options

                      Study Arms

                      ASSIGNED INTERVENTION

                      Study Arms

                      Experimental: Golcadomide Dose 1 + Rituximab

                      ASSIGNED INTERVENTION
                      • Drug: Golcadomide, Rituximab

                      Study Arms

                      Experimental: Golcadomide Dose 2 + Rituximab

                      ASSIGNED INTERVENTION
                      • Drug: Golcadomide, Rituximab

                      Study Arms

                      Experimental: Rituximab + Chemotherapy

                      ASSIGNED INTERVENTION
                      • Drug: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Bendamustine

                      Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you